PDCD1 and neoplasm: ICIs inhibit T-cell (programmed cell death protein 1 [PD-1] or cytotoxic T lymphocyte abtugen-4 [CTLA-4]) and tumor cell (programmed cell death-ligand 1 [PD-L1]) receptors, allowing T-cells to attack cancer cells.